



Greenhalgh, S. N., Matchett, K. P., Taylor, R. S., Huang, K., Li, J. T., Saeteurn, K., Donnelly, M. C., Simpson, E. E. M., Pollack, J. L., Atakilit, A., Simpson, K. J., Maher, J. J., Iredale, J. P., Sheppard, D., & Henderson, N. C. (2019). Loss of Integrin  $\alpha\beta 8$  in Murine Hepatocytes Accelerates Liver Regeneration. *American Journal of Pathology*, 189(2), 258-271. <https://doi.org/10.1016/j.ajpath.2018.10.007>

Publisher's PDF, also known as Version of record

License (if available):  
CC BY

Link to published version (if available):  
[10.1016/j.ajpath.2018.10.007](https://doi.org/10.1016/j.ajpath.2018.10.007)

[Link to publication record in Explore Bristol Research](#)  
PDF-document

This is the final published version of the article (version of record). It first appeared online via Elsevier at <https://doi.org/10.1016/j.ajpath.2018.10.007> . Please refer to any applicable terms of use of the publisher.

## University of Bristol - Explore Bristol Research

### General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:  
<http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>



GASTROINTESTINAL, HEPATOBILIARY, AND PANCREATIC PATHOLOGY

# Loss of Integrin $\alpha\text{v}\beta 8$ in Murine Hepatocytes Accelerates Liver Regeneration



Stephen N. Greenhalgh,<sup>\*</sup> Kylie P. Matchett,<sup>\*</sup> Richard S. Taylor,<sup>\*</sup> Katherine Huang,<sup>†</sup> John T. Li,<sup>†</sup> Koy Saeteurn,<sup>†</sup> Mhairi C. Donnelly,<sup>‡</sup> Eilidh E.M. Simpson,<sup>\*</sup> Joshua L. Pollack,<sup>†</sup> Amha Atakilit,<sup>§</sup> Kenneth J. Simpson,<sup>‡</sup> Jacquelyn J. Maher,<sup>¶</sup> John P. Iredale,<sup>\*||</sup> Dean Sheppard,<sup>†</sup> and Neil C. Henderson<sup>\*†</sup>

From the Centre for Inflammation Research,<sup>\*</sup> The Queen's Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom; the Lung Biology<sup>†</sup> and Liver<sup>¶</sup> Centers, Department of Medicine, and the Department of Pathology,<sup>§</sup> University of California, San Francisco, San Francisco, California; the Department of Hepatology,<sup>‡</sup> Scottish Liver Transplant Unit and University of Edinburgh, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom; and Senate House,<sup>||</sup> University of Bristol, Bristol, United Kingdom

Accepted for publication  
October 10, 2018.

Address correspondence to Neil C. Henderson, Ph.D., Centre for Inflammation Research, The Queen's Medical Research Institute, University of Edinburgh, 47 Little France Crescent, Edinburgh EH16 4TJ, UK. E-mail: [neil.henderson@ed.ac.uk](mailto:neil.henderson@ed.ac.uk)

Recent fate-mapping studies in mice have provided substantial evidence that mature adult hepatocytes are a major source of new hepatocytes after liver injury. In other systems, integrin  $\alpha\text{v}\beta 8$  has a major role in activating transforming growth factor (TGF)- $\beta$ , a potent inhibitor of hepatocyte proliferation. We hypothesized that depletion of hepatocyte integrin  $\alpha\text{v}\beta 8$  would increase hepatocyte proliferation and accelerate liver regeneration after injury. Using *Itgb8*<sup>fl<sup>ox</sup>/fl<sup>ox</sup></sup>; *Alb-Cre* mice to deplete hepatocyte  $\alpha\text{v}\beta 8$ , after partial hepatectomy, hepatocyte proliferation and liver-to-body weight ratio were significantly increased in *Itgb8*<sup>fl<sup>ox</sup>/fl<sup>ox</sup></sup>; *Alb-Cre* mice compared with control mice. Antibody-mediated blockade of hepatocyte  $\alpha\text{v}\beta 8$  *in vitro*, with assessment of TGF- $\beta$  signaling pathways by real-time quantitative PCR array, supported the hypothesis that integrin  $\alpha\text{v}\beta 8$  inhibition alters hepatocyte TGF- $\beta$  signaling toward a pro-regenerative phenotype. A diethylnitrosamine-induced model of hepatocellular carcinoma, used to examine the possibility that this pro-proliferative phenotype might be oncogenic, revealed no difference in either tumor number or size between *Itgb8*<sup>fl<sup>ox</sup>/fl<sup>ox</sup></sup>; *Alb-Cre* and control mice. Immunohistochemistry for integrin  $\alpha\text{v}\beta 8$  in healthy and injured human liver demonstrated that human hepatocytes express integrin  $\alpha\text{v}\beta 8$ . Depletion of hepatocyte integrin  $\alpha\text{v}\beta 8$  results in increased hepatocyte proliferation and accelerated liver regeneration after partial hepatectomy in mice. These data demonstrate that targeting integrin  $\alpha\text{v}\beta 8$  may represent a promising therapeutic strategy to drive liver regeneration in patients with a broad range of liver diseases. (*Am J Pathol* 2019; 189: 258–271; <https://doi.org/10.1016/j.ajpath.2018.10.007>)

Although the liver has a unique ability to regenerate, in many cases of liver disease this regenerative capacity is overwhelmed. A successful pro-regenerative therapy for the liver could have widespread application, reducing the need for transplantation in both acute and chronic liver failure, and potentially allowing more patients with primary or metastatic liver cancer to be treated successfully. Recent fate-mapping studies in mice have provided strong evidence that, in most murine models of liver injury and regeneration, restoration of liver mass occurs predominantly through self-duplication of hepatocytes.<sup>1,2</sup> Hence, identifying targets that promote proliferation and expansion of the preexistent hepatocyte population represents an attractive therapeutic approach to drive liver regeneration.

Transforming growth factor (TGF)- $\beta$  has pleiotropic roles in liver disease. In addition to its role as a major proinflammatory cytokine,<sup>3</sup> TGF- $\beta$  is also a potent repressor of hepatocyte proliferation.<sup>4–7</sup> Therefore, in principle, TGF- $\beta$  inhibition appears an attractive therapeutic strategy to promote hepatocyte proliferation and liver regeneration. An ideal therapy would target TGF- $\beta$

Supported by Wellcome Trust Clinical Training Fellowship 102762/Z/13/Z (S.N.G.), Wellcome Trust Senior Research Fellowship in Clinical Science 103749/Z/14/Z (N.C.H.), University of California, San Francisco Liver Center grant P30 DK026743 (N.C.H.), and Medical Research Council Program grant MR/J010766/1 (J.P.I.).

Disclosures: None declared.

with precision, allowing hepatocytes to escape the mitoinhibitory effects of TGF- $\beta$ , while not abrogating the positive effects of TGF- $\beta$  on extracellular matrix production and vascular remodeling during the regenerative process.<sup>8,9</sup> Furthermore, pan-TGF- $\beta$  blockade may result in a number of unwanted, off-target effects, such as induction of autoimmunity and hepatocarcinogenesis.<sup>10–12</sup> Therefore, a more nuanced, selective approach that targets the TGF- $\beta$  pathway to promote liver regeneration is required.

TGF- $\beta$  is predominantly stored within the extracellular matrix in a latent state, and much of the regulation of TGF- $\beta$  function results from precise, temporally and spatially restricted, extracellular activation of this latent complex.<sup>13</sup> The  $\alpha v$  integrins, transmembrane heterodimeric proteins comprising an  $\alpha v$  subunit and one of five  $\beta$  subunits, bind to an arginine-glycine-aspartate (RGD) motif present on the tip of an exposed loop within the latency-associated peptide that maintains TGF- $\beta$  in an inactive state.<sup>14</sup> All five  $\alpha v$  integrins have been shown to interact with the RGD motif present in the latency-associated peptide.<sup>15–19</sup> This integrin–RGD interaction, in the presence of mechanical force supplied by the integrin-expressing cell, enables the release of the active TGF- $\beta$  homodimer.<sup>20</sup>

Inhibition of myofibroblast  $\alpha v$  integrins in mice reduces fibrosis in multiple organs via a reduction in TGF- $\beta$  activation.<sup>21</sup> Furthermore, combined global knockout of integrins  $\alpha v \beta 6$  and  $\alpha v \beta 8$  phenocopies the developmental effects of loss of TGF- $\beta$ –1 and –3.<sup>22</sup> In the liver, expression of integrin  $\alpha v \beta 6$  appears restricted to activated cholangiocytes, transitional hepatocytes, and oval cells during biliary and portal fibrosis.<sup>23,24</sup> Conversely,  $\alpha v \beta 8$  expression by hepatic cell types has not been well characterized. Integrin  $\alpha v \beta 8$  has been shown to play an important role in TGF- $\beta$  activation in other systems, including dendritic cells,<sup>25–27</sup> regulatory T cells,<sup>28</sup> neuroepithelium,<sup>29</sup> and in fibroinflammatory airway disease.<sup>30</sup> Further, integrin  $\alpha v \beta 8$  inhibits proliferation of lung epithelium via TGF- $\beta$  activation.<sup>31</sup> Therefore, given the important role of  $\alpha v \beta 8$  in mediating TGF- $\beta$  activation in other organ systems and pathologic processes, we investigated the role of hepatocyte integrin  $\alpha v \beta 8$  in the context of liver regeneration. We hypothesized that depletion of integrin  $\alpha v \beta 8$  from hepatocytes would reduce local activation of TGF- $\beta$  and would result in increased hepatocyte proliferation and accelerated liver regeneration after liver injury.

## Materials and Methods

### Mice

Albumin-Cre (*Alb-Cre*) mice<sup>32</sup> were obtained from The Jackson Laboratory (Bar Harbor, ME), crossed with *Itgb8*<sup>fllox/fllox</sup> mice<sup>33</sup> obtained from Louis F. Reichardt (University of California, San Francisco, San Francisco, CA), and the resulting *Itgb8*<sup>fllox/fllox</sup>; *Alb-Cre* mice were maintained on a C57BL/6 background. *Pdgfrb-Cre* mice (also on a C57BL/6 background) were obtained from Ralf H. Adams (Max Planck

Institute for Molecular Biomedicine and University of Münster, Münster, Germany).<sup>34</sup> Mice used for all experiments were 8 to 16 weeks old and housed under specific pathogen-free conditions in the Animal Barrier Facility of the University of California, San Francisco, or the University of Edinburgh, UK. Genotyping of all mice was performed by PCR. Sample size was determined statistically before experimentation. Age- and sex-matched littermate controls were used for all experiments. Investigators (S.N.G., K.P.M., K.H., K.S., M.C.D., E.E.M.S., and N.C.H.) were blinded to mouse genotype, and experimental order was decided randomly. All experimental animal procedures were approved by the Institutional Animal Care and Use Committee of the University of California, San Francisco, or performed in accordance with the UK Home Office regulations.

### Two-Thirds Partial Hepatectomy

Two-thirds of the liver was surgically removed under isoflurane anesthesia as previously described.<sup>35</sup> All surgeries were performed in the first half of the day. To label proliferating hepatocytes, 5-bromo-2'-deoxyuridine (BrdU; 10280879001; Sigma-Aldrich, Gillingham, UK) was injected 2 hours before liver harvest (100 mg/kg intraperitoneally). Mice and livers were weighed at harvest to calculate liver-to-body weight ratio.

### Hepatocarcinogenesis Model

Male mice were injected with diethylnitrosamine (25 mg/kg intraperitoneally; Sigma-Aldrich) at 12 to 14 days. Mice were sacrificed at 40 weeks, and macroscopic tumors were counted and measured.

### Liver Biochemistry

Whole blood was collected immediately after death and allowed to clot, and serum was obtained by centrifugation ( $9391 \times g$  for 5 minutes twice). Samples were frozen at  $-20^{\circ}\text{C}$  pending analysis. Serum albumin, total bilirubin, alanine transaminase, and alkaline phosphatase measurements were determined by using commercial kits (Alpha Laboratories, Eastleigh, UK, for albumin, bilirubin, and alanine transaminase; Randox Laboratories, Crumlin, County Antrim, UK, for alkaline phosphatase) adapted for use on a Cobas Fara centrifugal analyzer (Roche Diagnostics, Welwyn Garden City, UK).

### Immunohistochemistry

Liver samples were fixed overnight at room temperature in either methacarn (60% methanol, 30% chloroform, 10% acetic acid) for BrdU immunohistochemistry (IHC) or 10% neutral-buffered formalin. Samples were then paraffin-embedded before sectioning.

No image processing was performed before quantitative analysis. Images presented in figures were contrast-enhanced by adjusting intensity minima and maxima. Images to be compared were processed identically and in a manner that preserved the visibility of dim and bright structures in the original image.

### BrdU IHC

Endogenous peroxidases were quenched with 0.3% H<sub>2</sub>O<sub>2</sub> in methanol, followed by consecutive 10-minute incubation steps with 0.1% trypsin (T7168; Sigma-Aldrich), warm 1.8 mol/L HCl, and 0.1 mol/L sodium tetraborate decahydrate (S9640; Sigma-Aldrich). Blocking and subsequent incubation steps used the Mouse on Mouse Elite Peroxidase Kit (PK2200; Vector Laboratories, Peterborough, UK). Primary antibody was mouse anti-BrdU (dilution 1:40; M0744; Dako, Agilent Technologies, Cheadle, UK). Detection was performed by using the Elite Vectastain ABC kit (PK7100; Vector Laboratories) and 3,3'-diaminobenzidine (K3468; Dako) before counterstaining, dehydration, and mounting. For each liver sample, approximately 3000 hepatocytes were counted to calculate the percentage of proliferating hepatocytes.

### GR1 (neutrophil)/F4/80 (Kupffer cell)/PDGFR $\beta$ (hepatic stellate cell) IHC

Antigen retrieval was performed with Tris-EDTA [platelet-derived growth factor receptor (PDGFR) $\beta$  only], endogenous peroxidases were quenched with 3% H<sub>2</sub>O<sub>2</sub>, Avidin/Biotin block was applied (SP-2001; Vector Laboratories) before blocking with 20% goat serum (GR1/PDGFR $\beta$ ) or rabbit serum (F4/80). Primary antibodies were applied for 2 hours at room temperature (PDGFR $\beta$ , dilution 1:500; ab32570; Abcam, Cambridge, UK) or overnight at 4°C (GR1, dilution 1:750; MAB1037; R&D, Abingdon, UK; F4/80, dilution 1:200; ab6640; Abcam). Secondary antibody (PDGFR $\beta$ —biotinylated goat anti-rabbit, dilution 1:1000; BA-1000; Vector Laboratories; GR1—biotinylated goat anti-rat, dilution 1:1000; BA-9401; F4/80—biotinylated rabbit anti-rat, dilution 1:200; BA-4001) was applied for 30 minutes at room temperature. Detection was performed by using the Elite Vectastain ABC kit and 3,3'-diaminobenzidine, before counterstaining, dehydration, and mounting. For each sample, 10 sequential fields were acquired at  $\times 20$  magnification, and the percentage of positive staining was calculated by using FIJI.<sup>36</sup>

### $\beta 8$ Integrin Subunit/Cleaved Caspase-3 IHC

Antigen retrieval was performed with Tris-EDTA ( $\beta 8$  integrin subunit) or sodium citrate (cleaved caspase-3), endogenous peroxidases were quenched with 3% H<sub>2</sub>O<sub>2</sub> before blocking with 20% horse serum. Primary antibody ( $\beta 8$  integrin subunit, dilution 1:500; ab80673; Abcam;

Cleaved Caspase-3, dilution 1:1000; 9664; Cell Signaling Technology, Leiden, The Netherlands) was applied overnight at 4°C. Detection was performed by using the ImmPRESS Polymerized Reporter Enzyme Staining System (MP7401; Vector Laboratories) and 3,3'-diaminobenzidine before counterstaining, dehydration, and mounting.

### Hematoxylin and Eosin Staining

Sections were baked at 55°C overnight before de-waxing and rehydration. Slides were then placed in Harris Hematoxylin (Thermo Fisher Scientific, Paisley, UK) for 5 minutes. After washing, slides were placed in 1% acid alcohol for 5 seconds, followed by Scott's tap water for 2 minutes. Slides were then transferred to Eosin Y solution (Thermo Fisher Scientific) for 2 minutes, followed by washing, dehydration, and mounting. For quantification of mitotic figures, a minimum of 1000 hepatocytes were counted per sample.

### Primary Mouse Hepatocyte Isolation

Primary mouse hepatocytes were isolated by retrograde perfusion of the liver with Liver Perfusion Medium (Thermo Fisher Scientific), followed by Liver Digest Medium (Thermo Fisher Scientific) at 37°C. When hepatocytes were visually dispersed within the liver capsule, the liver was removed to a sterile dish and minced with scissors to release the crude cell isolate. The cells were then suspended in Dulbecco's modified Eagle's medium/F-12 (Thermo Fisher Scientific) and pelleted twice. Hepatocytes were purified from the washed pellets by resuspension in culture medium and centrifugation through 50% equilibrated Percoll (GE Healthcare Life Sciences, Little Chalfont, UK).

### Standard Primary Hepatocyte Culture

Primary hepatocytes were isolated as described in the section above, resuspended in low-serum medium [Dulbecco's modified Eagle's medium (Thermo Fisher Scientific), 2.5% fetal bovine serum (Thermo Fisher Scientific), 2% L-glutamine (Thermo Fisher Scientific), 1% penicillin streptomycin (Thermo Fisher Scientific)], and plated onto collagen-coated wells (Collagen Type I; Millipore, Watford, UK) in a 6-well plate at a density of 500,000 cells per well. Either  $\beta 8$  integrin subunit blocking antibody<sup>26</sup> or nonbinding control antibody were added at 20  $\mu$ g/mL, and samples were incubated for 24 hours at 37°C in 5% CO<sub>2</sub>. Wells were then washed with phosphate-buffered saline (PBS), and cells were lysed as described in the following section.

### RT-qPCR

RNA was isolated from whole mouse liver, primary hepatocytes, or liver sinusoidal endothelial cells by using a RNeasy Mini Kit (whole liver, hepatocytes) or RNeasy Plus Micro Kit (liver sinusoidal endothelial cells; Qiagen, Manchester, UK).



cDNA transcription and real-time quantitative PCR (qPCR) were performed by using a SYBR-GreenER Two-Step qRT-PCR kit (Invitrogen, Thermo Fisher Scientific) or QuantiTect Reverse Transcription and SYBR Green PCR Kits (Qiagen). Samples were amplified on an ABI 7900HT thermocycler (Applied Biosystems, Thermo Fisher Scientific) and normalized to *Actb* and/or *Gapdh* expression. Primers used were as follows: *Actb*, 5'-TGTTACCAACTGGGACGACA-3' (forward) and 5'-GGGGTGTGTAAGGTCTCAA-3' (reverse); *Igfb8*, 5'-CTGAAGAAATACCCCGTGG-3' (forward) and 5'-ATGGGGAGGCATACAGTCT-3' (reverse). Quantitect Primer Assays (249990; Qiagen) were used for the following genes: *Ccna2* (QT00102151), *Ccnb1* (QT00152040), *Ccnd1* (QT00154595), *Ccne1* (QT00103495), *Cdkn1a* (QT00137053), *Cdkn1b* (QT01058708), *Gapdh* (QT01658692), and *Plat* (QT00133630).

To assess TGF- $\beta$  signaling, a custom RT<sup>2</sup> Profiler PCR array (330171; Qiagen) was designed which contained primer sequences for the genes shown in [Supplemental Table S1](#). RNA was isolated after primary hepatocyte culture as described in the section above and reversed transcribed by using the RT<sup>2</sup> First Strand Kit (330401; Qiagen). qPCR was performed by using RT<sup>2</sup> SYBR Green ROX qPCR Mastermix (330522; Qiagen) on an ABI 7900HT thermocycler, normalized to *Actb* and *Gapdh* expression.

### Hepatocyte Adhesion Assay

Adhesion was assessed by using a colorimetric ECM Cell Adhesion Array Kit (ECM540; Millipore) according to the manufacturer's instructions. Primary mouse hepatocytes were isolated as described above, plated in triplicate at 50,000 cells per well, and incubated for 2 hours at 37°C in 5% CO<sub>2</sub>. Absorbance was measured at 570 nm by using a Synergy HT microplate reader (BioTek, Swindon, UK). Relative absorbance was calculated by standardizing to absorbance in the Collagen I well, before calculation of mean relative absorbance for each extracellular matrix protein for each sample.

### Hepatocyte Proliferation Assay

Primary mouse hepatocytes were isolated as above and plated at 10,000 cells per well in 24-well plates (353847; Primaria; Corning, St David's Park, UK) in Dulbecco's modified Eagle's medium/F-12 supplemented with 15 mmol/L HEPES (H3375; Sigma-Aldrich), 10% fetal bovine serum, 1% insulin-transferrin-selenium (41400-045; Thermo Fisher Scientific), and 1% penicillin streptomycin. Cells were allowed to adhere for 4 hours before washing with PBS. Cells were then cultured for 48 hours in a low-serum version of the plating medium, containing only 0.5% fetal bovine serum. The  $\beta$ 8 integrin subunit blocking antibody or nonbinding control antibody was added at 20  $\mu$ g/mL. Growth factors [hepatocyte growth factor (HGF), PHG0254, and epidermal growth factor

(EGF), PMG8044; Thermo Fisher Scientific] were added at 40 ng/mL. Culture medium, antibodies, and growth factors were refreshed at 24 hours, at which time 10  $\mu$ mol/L EdU (5-ethynyl-2'-deoxyuridine; C10640; Thermo Fisher Scientific) was added. After the 48-hour culture period, cells were washed with PBS-BSA [PBS supplemented with 1% bovine serum albumin (BSA); A8806; Sigma-Aldrich] and then fixed by using 4% paraformaldehyde in PBS for 15 minutes at room temperature.


Proliferating hepatocytes were detected by using the Click-iT Plus EdU Alexa Fluor 647 Imaging Kit (C10640; Thermo Fisher Scientific). Briefly, fixed cells were washed with PBS-BSA and incubated in 0.5% Triton X-100 (T8787; Sigma-Aldrich) in PBS for 20 minutes at room temperature. After washing, the Click-iT Plus reaction cocktail was added, and cells were incubated for 30 minutes at room temperature and protected from light. The cells were washed again and then incubated in 5  $\mu$ g/mL Hoechst 33342 (Thermo Fisher Scientific) for 30 minutes at room temperature and protected from light. Finally, cells were washed with PBS and imaged. Imaging was performed by using an LSM780 confocal microscope system (Carl Zeiss Ltd, Cambridge, UK). Tiled images were acquired, with three non-overlapping areas of 18  $\mu$ m<sup>2</sup> imaged per well. Imaris version 8.4.1 (Bitplane AG, Zurich, Switzerland) was used to identify the total (Hoechst-positive) nuclei number and the number of EdU-positive nuclei, and the percentage of proliferating nuclei was calculated.

### Whole Liver Microarray


Sample preparation, labeling, and array hybridizations were performed by using the Agilent GE 4  $\times$  44 Mouse microarray platform (Agilent Technologies, Palo Alto, CA). Total RNA quality was assessed by using a Pico Chip on an Agilent 2100 Bioanalyzer, and RNA was amplified and labeled with cyanine 3—cytidine-5'-triphosphate by using the Agilent Technologies low RNA input fluorescent linear amplification kits according to the manufacturer's protocol. Labeled cRNA was assessed by using the Nanodrop ND-100 (Nanodrop Technologies, Inc., Wilmington DE), and equal amounts of cyanine 3-labeled target were hybridized to Agilent whole mouse genome 4  $\times$  44K Ink-jet arrays (G4122F; Agilent Technologies). Hybridizations were performed for 14 hours, according to the manufacturer's protocol. Arrays were scanned by using the Agilent Technologies microarray scanner and raw signal intensities were extracted with Agilent Feature Extraction version 10.5 software. Raw data are accessible at the Gene Expression Omnibus repository (<http://www.ncbi.nlm.nih.gov/geo>; accession number GSE111591).

### Human Liver Tissue

De-identified sections of uninjured and fibrotic human liver tissue were provided by the Lothian NRS Bioresource



**Figure 1** Genetic depletion of hepatocyte integrin  $\alpha v \beta 8$  accelerated liver regeneration. **A:** Real-time quantitative PCR of *Itgb8* expression in hepatocytes isolated from control and *Itgb8<sup>fllox/fllox</sup>; Alb-Cre* ( $\beta 8$ -AlbCre) mice. **B:** Quantitation of 5-bromo-2'-deoxyuridine (BrdU)<sup>+</sup> hepatocyte nuclei in control and  $\beta 8$ -AlbCre mice after partial hepatectomy. **C:** Representative images from BrdU immunostaining of liver sections from control and  $\beta 8$ -AlbCre mice at 0 and 48 hours after partial hepatectomy. **D** and **E:** Quantitation of hepatocyte mitoses (**D**) and liver-to-body weight ratio (**E**) in control and  $\beta 8$ -AlbCre mice after partial hepatectomy. **F:** Serum biochemistry [total bilirubin, alanine transaminase (ALT), alkaline phosphatase (ALP), albumin] from uninjured control and  $\beta 8$ -AlbCre mice. **G** and **H:** Quantification and representative images from F4/80 (Kupffer cell; **G**) and platelet-derived growth factor receptor (PDGFR) $\beta$  (hepatic stellate cell; **H**) immunostaining of liver tissue from uninjured control and  $\beta 8$ -AlbCre mice. Data are expressed as means  $\pm$  SEM.  $n = 3$  control and  $\beta 8$ -AlbCre mice (**A**);  $n = 3$  to 6 control and  $\beta 8$ -AlbCre mice per time point (**B–E**);  $n = 6$  control and  $\beta 8$ -AlbCre mice (**F–H**). \* $P < 0.05$ , \*\* $P < 0.01$ , and \*\*\*\* $P < 0.0001$ . Scale bars: 100  $\mu$ m (**C** and **G**).



**Figure 2** Depletion of hepatocyte integrin  $\alpha\text{v}\beta 8$  did not alter inflammatory phenotype after partial hepatectomy. **A–C:** Quantification and representative images from F4/80 (Kupffer cell; **A**), GR1 (neutrophil; **B**), and platelet-derived growth factor receptor (PDGFR) $\beta$  (hepatic stellate cell; **C**) immunostaining of liver tissue from control and *Itgb8<sup>fllox/fllox</sup>;Alb-Cre* ( $\beta 8$ -AlbCre) mice at 48 hours after partial hepatectomy. **D:** Quantitation of 5-bromo-2'-deoxyuridine (BrdU) $^{+}$  hepatocyte nuclei and representative images of BrdU immunostaining of liver tissue from control and *Itgb8<sup>fllox/fllox</sup>;Pdgfrb-Cre* ( $\beta 8$ -PdgfrbCre) mice at 48 hours after partial hepatectomy. Data are expressed as means  $\pm$  SEM.  $n = 5$  control and  $\beta 8$ -AlbCre mice (**A–C**);  $n = 4$  and 8 control and  $\beta 8$ -PdgfrbCre mice (**D**). Scale bar = 100  $\mu\text{m}$ .

with approval from Tissue Governance. Samples of acetaminophen-injured human liver tissue were obtained as part of the Pathophysiology of Acute Liver Injury study. This study was approved by the Scotland A Research Ethics Committee and National Health Service Lothian Research and Development.

### Statistical Analysis

The statistical significance of differences between groups was calculated with a two-tailed  $t$ -test or  $U$ -test as appropriate. Differences with a  $P$  value  $< 0.05$  were considered statistically significant. PCR data obtained for individual genes were log-transformed before analysis, and a Bonferroni correction was applied to account for multiple testing. PCR array data were standardized as previously reported,<sup>37</sup> to identify genes in test samples with a 95% CI for standardized relative fold change that did not overlap 1 (the value assigned to the fold change for the same gene in control samples).

For microarray analysis, differential gene expression was examined with the R package limma version 3.32.7.<sup>38</sup> Quality control was performed by identifying outliers in the log2 intensity between arrays and comparison of multidimensional scaling of distances between microarray


expression profiles. Background correction was conducted according to the *normexp* method, and the data were normalized by using the *quantile* normalization method.<sup>39,40</sup> A two-way analysis of variance linear model was fitted to the comparison to estimate the mean  $M$  values and to calculate moderated  $t$ -statistic, B statistic, false discovery rate, and  $P$  value for each gene for the comparison of interest. Adjusted  $P$  values were produced by the method proposed by Holm.<sup>41</sup> Gene Ontology (GO) analysis was performed with the R package topGO version 2.28.0,<sup>42</sup> and the *elim* algorithm, combined with the Fisher exact test, was used to calculate the enrichment scores for each of the GO terms.

### Results

#### Depletion of Hepatocyte Integrin $\alpha\text{v}\beta 8$ Leads to Increased Hepatocyte Proliferation and Accelerated Liver Regeneration

To deplete integrin  $\alpha\text{v}\beta 8$  in hepatocytes, *Itgb8<sup>fllox/fllox</sup>;Alb-Cre* mice were generated.<sup>32,33</sup> Primary hepatocytes were isolated from *Itgb8<sup>fllox/fllox</sup>;Alb-Cre* mice and Cre-negative littermate controls. qPCR for *Itgb8* confirmed expression in control hepatocytes and successful depletion in





**Figure 3** Investigation of the mechanisms mediating the pro-regenerative effect of hepatocyte integrin  $\alpha v \beta 8$  depletion. **A** and **B**: Whole liver expression of cell cycle genes *Ccna2* (**A**) and *Ccnb1* (**B**) from control and *Itgb8<sup>fllox/fllox</sup>; Alb-Cre* ( $\beta 8$ -AlbCre) mice after partial hepatectomy. **C**: Isolated hepatocytes from control and  $\beta 8$ -AlbCre mice were tested in a colorimetric extracellular matrix adhesion assay. **D**: Whole liver expression of *Itgb8* after partial hepatectomy. **E**: Schematic of experimental design to test the effect of a  $\beta 8$  integrin subunit blocking antibody on hepatocyte expression of transforming growth factor- $\beta$ -responsive genes. **F**: Fold regulation of genes from the real-time quantitative PCR (qPCR) array with a detectable change in hepatocyte expression after culture with  $\beta 8$  integrin subunit blocking antibody. **G**: Proliferation of primary hepatocytes cultured for 48 hours with  $\beta 8$  integrin subunit blocking antibody or control antibody in culture medium (Control) and with addition of either epidermal growth factor (EGF) or hepatocyte growth factor (HGF) or with both. Data are expressed as means  $\pm$  SEM.  $n = 4$  to 6 control and  $\beta 8$ -AlbCre mice per time point (**A** and **B**);  $n = 4$  control and  $\beta 8$ -AlbCre mice (**C**);  $n = 3$  to 6 mice per time point (**D**);  $n = 3$  mice (**F** and **G**). BSA, bovine serum albumin; Col, collagen.


hepatocytes isolated from *Itgb8<sup>fllox/fllox</sup>; Alb-Cre* mice (Figure 1A). Assessment of hepatocyte proliferation after two-thirds partial hepatectomy showed significantly increased proliferation in *Itgb8<sup>fllox/fllox</sup>; Alb-Cre* mice at 36, 48, and 72 hours after liver injury compared with control mice (Figure 1, B and C). This increased hepatocyte proliferation was not followed by an increase in hepatocyte apoptosis at day 5 after partial hepatectomy, when liver regeneration was nearing completion in the *Itgb8<sup>fllox/fllox</sup>; Alb-Cre* mouse (Supplemental Figure S1). Interestingly, the proportion of hepatocyte mitoses (identified morphologically) was decreased in *Itgb8<sup>fllox/fllox</sup>; Alb-Cre* mice at 72 hours after liver injury compared with control mice (Figure 1D). However, liver-to-body weight ratio was significantly increased in *Itgb8<sup>fllox/fllox</sup>; Alb-Cre* mice at 72 and 96 hours after partial hepatectomy, demonstrating that the increase in hepatocyte proliferation in *Itgb8<sup>fllox/fllox</sup>; Alb-Cre* mice detected by BrdU IHC resulted in accelerated

restoration of liver mass compared with control mice (Figure 1E).

### Depletion of Hepatocyte Integrin $\alpha v \beta 8$ Does Not Alter Baseline Hepatocyte Proliferation or Subsequent Inflammatory Phenotype

Because integrin  $\alpha v \beta 8$  is able to activate TGF- $\beta$ , a well-characterized suppressor of epithelial proliferation, the effect of genetic depletion of hepatocyte  $\alpha v \beta 8$  on baseline hepatocyte proliferation or liver-to-body weight ratio was assessed. Hepatocyte BrdU incorporation and mitoses and liver-to-body weight ratio were measured in uninjured *Itgb8<sup>fllox/fllox</sup>; Alb-Cre* mice and control mice (Figure 1, B, D, and E), and no difference was found in any of these variables between groups. Furthermore, no difference was found in baseline liver biochemistry, hepatic morphology, or resident nonparenchymal cell populations [Kupffer cells





**Figure 4** Microarray analysis of whole liver (uninjured and 24 hours after partial hepatectomy) from control and *Itgb8<sup>flox/flox</sup>;Alb-Cre* ( $\beta 8$ -AlbCre) mice. **A**: Summary of the number of transcripts with significant changes in expression after partial hepatectomy in  $\beta 8$ -AlbCre and control mice. **B** and **C**: The top 10 Gene Ontology (GO) terms enriched in those genes either up-regulated (**B**) or down-regulated (**C**) exclusively in  $\beta 8$ -AlbCre mice after partial hepatectomy.  $n = 4$  control and  $\beta 8$ -AlbCre mice per group per time point.

and hepatic stellate cells (HSCs)] between uninjured *Itgb8<sup>flox/flox</sup>;Alb-Cre* mice and control mice (Figure 1, F–H, Supplemental Figure S2). After partial hepatectomy, no difference was found in hepatic inflammation (Kupffer cells or neutrophils) or HSC immunostaining (Figure 2, A–C). This suggested that the increased liver regeneration observed after partial hepatectomy in *Itgb8<sup>flox/flox</sup>;Alb-Cre* mice was not due to differences in degree of initial injury or the subsequent inflammatory response.


### Depletion of HSC Integrin $\alpha\text{v}\beta 8$ Does Not Lead to Increased Hepatocyte Proliferation

Integrin  $\alpha\text{v}\beta 8$  is also expressed on HSCs.<sup>21</sup> Because HSCs have been shown to play an important regulatory role in liver regeneration,<sup>43,44</sup> mice in which integrin  $\alpha\text{v}\beta 8$  had been depleted from HSCs (*Itgb8<sup>flox/flox</sup>;Pdgrb-Cre*) were used to examine the role of HSC integrin  $\alpha\text{v}\beta 8$  during liver regeneration. After two-thirds partial hepatectomy, no significant difference was found in hepatocyte proliferation between *Itgb8<sup>flox/flox</sup>;Pdgrb-Cre* mice and control mice (Figure 2D). Liver sinusoidal endothelial cells have also

been shown to play a key role in liver regeneration.<sup>45–47</sup> However, integrin  $\alpha\text{v}\beta 8$  expression was not observed in liver sinusoidal endothelial cells by qPCR.

### Assessment of Hepatic Cell Cycle Genes after Depletion of Hepatocyte Integrin $\alpha\text{v}\beta 8$ and Partial Hepatectomy

To examine whether depletion of hepatocyte integrin  $\alpha\text{v}\beta 8$  might have a direct effect on the cell cycle, the expression of genes with key roles in cell cycle regulation was measured at multiple time points after partial hepatectomy. Overall, partial hepatectomy resulted in expected changes in gene expression in whole liver from both *Itgb8<sup>flox/flox</sup>;Alb-Cre* mice and control mice (Figure 3, A and B, Supplemental Figure S3). A trend toward increased expression of *Ccna2* and *Ccnb1* was found in *Itgb8<sup>flox/flox</sup>;Alb-Cre* mice compared with control mice; however, this trend did not reach statistical significance at any time point (Figure 3, A and B). Analysis of other cell cycle–related genes (*Ccnd1*, *Ccne1*, *Cdkn1a*, *Cdkn1b*) showed no difference between *Itgb8<sup>flox/flox</sup>;Alb-Cre* mice and control mice (Supplemental Figure S3).



**Figure 5** Depletion of hepatocyte integrin  $\alpha v\beta 8$  did not increase hepatocellular carcinoma (HCC) in mice, whereas human hepatocytes expressed integrin  $\alpha v\beta 8$  in acute and chronic liver disease. **A:** Schematic of mouse model of HCC. **B:** Representative images of livers from control and *Itgb8<sup>flox/flox</sup>; Alb-Cre* ( $\beta 8$ -AlbCre) mice at harvest. **C and D:** Quantification of tumor number (**C**) and median tumor size (**D**) in control and  $\beta 8$ -AlbCre mice at 40 weeks (horizontal bar indicates mean). **E:** Representative low- and high-power images of  $\beta 8$  integrin subunit immunostaining in uninjured human liver tissue, after acetaminophen overdose, or in cirrhosis.  $n = 16$  and  $14$  control and  $\beta 8$ -AlbCre mice (**C and D**);  $n = 5$  uninjured human liver tissue samples (**E**);  $n = 5$  acetaminophen overdose samples (**E**);  $n = 6$  cirrhosis samples (**E**). Scale bars:  $250\ \mu\text{m}$  (top row; **E**);  $100\ \mu\text{m}$  (bottom row; **E**). DEN = diethylnitrosamine.

### Depletion of Integrin $\alpha v\beta 8$ on Hepatocytes Does Not Alter Adhesion to Multiple Matrix Proteins Present in Normal and Regenerating Liver

Integrin  $\alpha v\beta 8$  binds extracellular matrix ligands such as vitronectin, fibronectin, collagen IV, and fibronectin.<sup>48,49</sup> To test whether depletion of integrin  $\alpha v\beta 8$  on hepatocytes altered adhesion to cell matrix proteins present in normal and regenerating liver, an *in vitro* cell adhesion assay with multiple different matrix substrates was used. No difference was found in adhesion between *Itgb8<sup>flox/flox</sup>; Alb-Cre* and control hepatocytes across all seven matrix proteins tested (Figure 3C), suggesting that altered hepatocyte adhesion was not responsible for the pro-regenerative phenotype observed in *Itgb8<sup>flox/flox</sup>; Alb-Cre* mice.

### Inhibition of Integrin $\alpha v\beta 8$ Modulates TGF- $\beta$ -Responsive Genes in Hepatocytes

Integrin  $\alpha v\beta 8$  has previously been shown to play a key role in the activation of latent TGF- $\beta$ ,<sup>25–31</sup> a potent inhibitor of hepatocyte proliferation.<sup>5–7</sup> Therefore, we hypothesized that depletion of hepatocyte integrin  $\alpha v\beta 8$  might promote hepatocyte proliferation through modulation of TGF- $\beta$  signaling pathways. The time course of hepatic *Itgb8* expression after partial hepatectomy supported a role for integrin  $\alpha v\beta 8$  as a suppressor of hepatocyte proliferation during liver regeneration (Figure 3D). Hepatic *Itgb8* expression fell markedly in the 24 hours immediately after partial hepatectomy, and this down-regulation appeared to be permissive for hepatocyte proliferation. At the same time

as the liver approached full restoration of its functional mass at 5 days after partial hepatectomy, hepatocyte *Itgb8* expression peaked at 10 times baseline expression, consistent with a role for integrin  $\alpha$ v $\beta$ 8 as a brake on hepatocyte proliferation (Figure 3D).

Detecting the modulation of TGF- $\beta$  activation in the hepatocyte regenerative niche is challenging, because it is not possible to measure the levels of active TGF- $\beta$  in tissue directly. Therefore, an experiment was designed to examine how inhibition of integrin  $\alpha$ v $\beta$ 8 might modulate TGF- $\beta$ -responsive genes in primary mouse hepatocytes (Figure 3E). First, a custom qPCR array was designed, containing 87 genes either shown to be responsive to TGF- $\beta$  signaling in hepatocytes<sup>50</sup> or comprising components of the TGF- $\beta$  pathway (Supplemental Table S1). Primary murine hepatocytes were isolated from wild-type mice and plated onto collagen in the presence of either a  $\beta$ 8 integrin subunit blocking antibody or a nonbinding control antibody.<sup>26</sup> After incubation for 24 hours, hepatocytes were lysed, RNA was extracted, and gene expression was quantified by using the custom qPCR array. Data were then standardized as previously described by Willems et al.<sup>37</sup> After culture with  $\beta$ 8 integrin subunit blocking antibody, 20 genes in the qPCR array were found to have a detectable change in expression with a 95% CI, which did not overlap control values (Figure 3F). Of these, 12 genes showed >10% up- or down-regulation compared with controls, with 10 of 12 responding as predicted. *Plat*, encoding tissue plasminogen activator (tPA), showed the greatest up-regulation. Hepatocyte expression of *Plat* has been shown to decrease in the presence of TGF- $\beta$ ,<sup>50</sup> whereas expression increased threefold in wild-type hepatocytes treated with  $\beta$ 8 integrin subunit blocking antibody. Increased expression of *Plat* was not observed when hepatocytes from *Itgb8<sup>fllox/fllox</sup>;Alb-Cre* mice were treated with  $\beta$ 8 integrin subunit blocking antibody, suggesting the observed response was specific to  $\beta$ 8 integrin subunit inhibition (Supplemental Figure S4). Conversely, hepatocyte expression of the TGF- $\beta$ -responsive gene *Hmox1* (heme oxygenase 1) was down-regulated in the presence of  $\beta$ 8 integrin subunit blocking antibody. These data indicated that inhibition of integrin  $\alpha$ v $\beta$ 8 modulated TGF- $\beta$ -responsive genes in hepatocytes, suggesting a possible mechanism through which integrin  $\alpha$ v $\beta$ 8 depletion promoted hepatocyte proliferation.

### Inhibition of Hepatocyte Integrin $\alpha$ v $\beta$ 8 Does Not Alter the Proliferative Response to Mitogenic Growth Factors

HGF and EGF are key drivers of liver regeneration.<sup>8</sup> To investigate whether integrin  $\alpha$ v $\beta$ 8 might have a role in regulating the hepatocyte response to these direct mitogens, the effect of  $\beta$ 8 integrin subunit inhibition during *in vitro* proliferation of primary hepatocytes in response to EGF and HGF was examined. A robust increase in hepatocyte proliferation was achieved with addition of either EGF or HGF, or with both, compared with standard culture medium

(Figure 3G). However, inhibition of integrin  $\alpha$ v $\beta$ 8 had no effect on the degree of *in vitro* hepatocyte proliferation. This suggested that the accelerated liver regeneration observed after hepatocyte integrin  $\alpha$ v $\beta$ 8 depletion did not occur via modulation of HGF or EGF downstream signaling pathways.

### Microarray Analysis of Whole Liver from Control and *Itgb8<sup>fllox/fllox</sup>;Alb-Cre* Mice

To explore further the potential mechanisms by which inhibition of integrin  $\alpha$ v $\beta$ 8 increased hepatocyte proliferation and accelerated liver regeneration, global gene expression changes were examined by microarray analysis of whole liver. Samples were obtained from control and *Itgb8<sup>fllox/fllox</sup>;Alb-Cre* mice before and at 24 hours after partial hepatectomy. From 26,136 transcripts, 1080 showed statistically significant differential expression after partial hepatectomy. Of these, 330 occurred only in the *Itgb8<sup>fllox/fllox</sup>;Alb-Cre* mouse (Figure 4A). GO analysis was performed on the differentially expressed genes. The dominant GO terms enriched in genes up-regulated exclusively in *Itgb8<sup>fllox/fllox</sup>;Alb-Cre* mice after partial hepatectomy are shown in Figure 4B. Most terms related to cytoskeletal organization and cellular adhesion. Similarly, the dominant GO terms enriched in genes down-regulated exclusively in *Itgb8<sup>fllox/fllox</sup>;Alb-Cre* mice after partial hepatectomy are shown in Figure 4C. These terms were relatively nonspecific, relating to a range of intracellular metabolic processes.

Given the increased hepatocyte proliferation observed after partial hepatectomy in *Itgb8<sup>fllox/fllox</sup>;Alb-Cre* mice, changes in expression of genes known to regulate the cell cycle were specifically studied. However, when comparing samples after partial hepatectomy from *Itgb8<sup>fllox/fllox</sup>;Alb-Cre* mice and control mice, no significant difference in the expression of cell cycle genes was detected by microarray. This mirrored the findings of both our examination of cell cycle gene expression in whole liver before and after partial hepatectomy (Figure 3, A and B and Supplemental Figure S3) and the qPCR array in cultured hepatocytes treated with  $\beta$ 8 integrin subunit blocking antibody, in which no consistent changes in gene expression were noted in the 10 cell cycle and proliferation genes included in the array (Supplemental Table S1).

### Depletion of Hepatocyte Integrin $\alpha$ v $\beta$ 8 Does Not Increase Tumor Formation in a Mouse Model of HCC

In addition to promoting hepatocyte proliferation, disruption of TGF- $\beta$  signaling can accelerate the development of hepatocellular carcinoma (HCC) in mice after diethylnitrosamine administration.<sup>12</sup> Because depletion of integrin  $\alpha$ v $\beta$ 8 on hepatocytes increased hepatocyte proliferation and accelerated liver regeneration after injury, and blockade of hepatocyte integrin  $\alpha$ v $\beta$ 8 *in vitro* modulated TGF- $\beta$ -responsive genes, the possibility that this pro-proliferative phenotype



might increase the risk of HCC development was also assessed. *Itgb8<sup>flox/flox</sup>;Alb-Cre* and control mice were injected with diethylnitrosamine at 12 to 14 days of age to induce HCC (Figure 5A). After sacrifice at 40 weeks, the number and size of tumors in each liver were quantified (Figure 5B). No difference was found in either tumor number or median tumor size between *Itgb8<sup>flox/flox</sup>;Alb-Cre* and control mice (Figure 5, C and D). This indicated that depletion of hepatocyte integrin  $\alpha\text{v}\beta 8$  did not predispose to increased tumor formation in this mouse model of HCC.

### Human Hepatocytes Express Integrin $\alpha\text{v}\beta 8$ and Represent a Viable Therapeutic Target to Promote Liver Regeneration in Patients with Liver Disease

To assess the potential utility of integrin  $\alpha\text{v}\beta 8$  as a therapeutic target to promote hepatocyte proliferation and liver regeneration in patients with liver disease, the expression of integrin  $\alpha\text{v}\beta 8$  was assessed in samples of human liver. Uninjured liver tissue and tissue obtained from patients with acute liver failure secondary to acetaminophen overdose or from patients with cirrhosis were stained for the  $\beta 8$  integrin subunit. Widespread expression in hepatocytes was detected in all samples, demonstrating that integrin  $\alpha\text{v}\beta 8$  could be a viable potential therapeutic target in patients with a broad range of liver diseases (Figure 5E).

## Discussion

We show that depletion of hepatocyte integrin  $\alpha\text{v}\beta 8$  leads to increased hepatocyte proliferation and accelerated liver regeneration after partial hepatectomy in mice. The time course of hepatic *Itgb8* expression after partial hepatectomy, namely a rapid down-regulation followed by rebound up-regulation as the liver returns to its normal size, is consistent with a role for integrin  $\alpha\text{v}\beta 8$  as a brake on hepatocyte proliferation. This anti-proliferative role for integrin  $\alpha\text{v}\beta 8$  appears to be mediated via TGF- $\beta$ , rather than altered hepatocyte adhesion, because blocking integrin  $\alpha\text{v}\beta 8$  on hepatocytes alters TGF- $\beta$ -responsive gene expression. Of importance, the augmentation in hepatocyte proliferation in *Itgb8<sup>flox/flox</sup>;Alb-Cre* mice was not accompanied by increased susceptibility to hepatocellular tumor formation. Finally, human hepatocytes also express integrin  $\alpha\text{v}\beta 8$  in both acute and chronic liver disease; therefore, integrin  $\alpha\text{v}\beta 8$  represents a viable therapeutic target to promote liver regeneration in patients with a broad range of liver diseases.

Integrin  $\alpha\text{v}\beta 8$  has previously been shown to have a key regulatory role in the activation of latent TGF- $\beta$ .<sup>25–31</sup> The inhibitory effect of active TGF- $\beta$  on hepatocyte proliferation is well established, including evidence demonstrating tonic inhibition of hepatocyte proliferation in the uninjured liver.<sup>5–7</sup> The rapid down-regulation of hepatic *Itgb8* expression observed after partial hepatectomy is in line with

the hypothesis that a reduction in integrin  $\alpha\text{v}\beta 8$ -mediated activation of TGF- $\beta$  is permissive for a pro-regenerative environment in the liver. To demonstrate subtle changes in activation status of TGF- $\beta$  within the hepatic regenerative niche is challenging, given the magnitude and localized nature of these changes and also the small amount of remnant tissue present after two-thirds partial hepatectomy. However, inhibition of hepatocyte integrin  $\alpha\text{v}\beta 8$  *in vitro*, using a  $\beta 8$  integrin subunit blocking antibody, resulted in changes in expression of multiple TGF- $\beta$ -responsive genes such as *Plat* and *Hmox1*. tPA, encoded by *Plat*, can activate HGF<sup>51</sup> and has been shown to play a role in liver lobule reorganization after acute injury.<sup>52</sup> Knockout of tPA in mice worsens injury after bile duct ligation, but this phenotype is reversed by administration of HGF.<sup>53</sup> These data suggest that the regulatory role of integrin  $\alpha\text{v}\beta 8$  during hepatocyte proliferation is, at least in part, mediated via TGF- $\beta$  signaling and that integrin  $\alpha\text{v}\beta 8$  depletion or inhibition may drive hepatocyte proliferation through tPA-mediated activation of HGF. Inhibition of hepatocyte integrin  $\alpha\text{v}\beta 8$  did not alter the proliferative response to stimulation with EGF and HGF *in vitro*, suggesting that the accelerated liver regeneration observed after hepatocyte integrin  $\alpha\text{v}\beta 8$  depletion does not occur via modulation of HGF or EGF downstream signaling pathways.

Detectable changes in the expression of genes that regulate the cell cycle were identified after partial hepatectomy, similar to those previously reported,<sup>54</sup> but did not differ between *Itgb8<sup>flox/flox</sup>;Alb-Cre* mice and control mice. Inhibiting integrin  $\alpha\text{v}\beta 8$  *in vitro* also had no effect on expression of cell cycle genes, as measured by qPCR gene array. This would suggest that depletion of integrin  $\alpha\text{v}\beta 8$  on hepatocytes does not appear to change the kinetics of cell cycle regulation in the individual cell. Instead, depletion of hepatocyte integrin  $\alpha\text{v}\beta 8$  may promote liver regeneration by permitting a greater number of hepatocytes to escape the antiproliferative effects of active TGF- $\beta$ . The observation of a reduction in the proportion of hepatic mitoses in *Itgb8<sup>flox/flox</sup>;Alb-Cre* mice compared with control mice at 72 hours after partial hepatectomy is difficult to reconcile with the increase in BrdU incorporation and the accelerated restoration of total liver mass. Although no change was detected in cell cycle kinetics, if the overall time in M phase were reduced in hepatocytes of *Itgb8<sup>flox/flox</sup>;Alb-Cre* mice, this could decrease the proportion of mitotic hepatocytes at any single point in time. Previous work has demonstrated a strong effect of circadian rhythm on hepatocyte entry into M phase after partial hepatectomy in mice, an effect not seen when assessing BrdU incorporation.<sup>55</sup> However, in this study, partial hepatectomy was always performed in the morning and experimental order was randomized, so this should not account for differences between *Itgb8<sup>flox/flox</sup>;Alb-Cre* mice and control mice.

To screen for additional pathways that might be regulated by integrin  $\alpha\text{v}\beta 8$ , gene expression was assessed by using microarray in whole liver samples from *Itgb8<sup>flox/flox</sup>;Alb-Cre*



and control mice, comparing gene expression in uninjured liver and 24 hours after partial hepatectomy. Despite observing a large number of changes in gene expression (330) after partial hepatectomy that were restricted to *Itgb8<sup>fllox/flox</sup>;Alb-Cre* mice, there were again no differences in expression of genes that regulated the cell cycle or proliferation compared with control mice. The failure to detect changes in expression of genes that regulated the cell cycle may also reflect limitations in sensitivity, particularly of the microarray technique, when applied to whole liver lysates from *Itgb8<sup>fllox/flox</sup>;Alb-Cre* and control mice. Even after partial hepatectomy, only a minority of hepatocytes will be proliferating at any one time, and the presence of non-parenchymal cell mRNA in the whole liver lysates that were analyzed will further reduce the signal-to-noise ratio.

GO analysis of genes up-regulated only in *Itgb8<sup>fllox/flox</sup>;Alb-Cre* mice after partial hepatectomy returned multiple terms that related to cytoskeletal organization and extracellular adhesion. Integrins are well known for their role in extracellular adhesion and their cytoplasmic domains can bind the cytoskeleton.<sup>14</sup> However, it has previously been suggested that the cytoplasmic domain of the  $\beta 8$  subunit does not bind the cytoskeleton.<sup>48</sup> Furthermore, no difference was found in the ability of hepatocytes isolated from *Itgb8<sup>fllox/flox</sup>;Alb-Cre* and control mice to adhere to multiple extracellular matrix proteins found in both normal and regenerating liver.

Targeting of TGF- $\beta$  pathways has been a major focus of research across several fields, particularly in the context of inflammation, wound healing, and oncogenesis. Unfortunately, global inhibition of TGF- $\beta$  signaling can be associated with serious, undesirable effects, including excessive inflammation and development of neoplasia.<sup>10–12</sup> This is highly likely to be due to the pleiotropic, context-dependent functions of TGF- $\beta$ . Selective targeting of TGF- $\beta$  activation by inhibition of integrin  $\alpha\text{v}\beta 8$  in the hepatic regenerative niche may potentially avoid many of the adverse effects noted with pan-TGF- $\beta$  blockade while still promoting the desired effects on hepatocyte proliferation and liver regeneration. Of importance, these results did not demonstrate an increase in either hepatic inflammation or carcinogenesis in mice after depletion of hepatocyte integrin  $\alpha\text{v}\beta 8$ .

Human hepatocytes express integrin  $\alpha\text{v}\beta 8$  in uninjured liver after acute hepatic injury secondary to acetaminophen overdose and also in cirrhosis. Therefore, hepatocyte integrin  $\alpha\text{v}\beta 8$  appears to be a viable translational target. There are potentially multiple clinical scenarios to which integrin  $\alpha\text{v}\beta 8$  inhibition could be applied. For example, using  $\alpha\text{v}\beta 8$  inhibition as a pro-regenerative therapy in the setting of acute liver failure may obviate the requirement for, or buy more time before, liver transplantation. Furthermore, combination with antifibrotic therapies could permit the restoration of functional, parenchymal liver mass in tandem with a reduction in fibrosis in patients with chronic liver disease. It might also allow more patients with primary or metastatic liver cancer to be treated successfully.

## Conclusion

Depletion of integrin  $\alpha\text{v}\beta 8$  on murine hepatocytes leads to increased hepatocyte proliferation and accelerated liver regeneration. Targeting integrin  $\alpha\text{v}\beta 8$  may therefore represent a promising therapeutic strategy to drive liver regeneration in patients with a broad range of liver diseases.

## Acknowledgments

We thank Chris Her and Sandra Huling (University of California, San Francisco) and Jon Henderson (University of Edinburgh) for expert technical assistance and Garrett Roll and Holger Willenbring (University of California, San Francisco) for helpful discussions.

## Supplemental Data

Supplemental material for this article can be found at <https://doi.org/10.1016/j.ajpath.2018.10.007>.

## References

1. Malato Y, Naqvi S, Schürmann N, Ng R, Wang B, Zape J, Kay MA, Grimm D, Willenbring H: Fate tracing of mature hepatocytes in mouse liver homeostasis and regeneration. *J Clin Invest* 2011, 121: 4850–4860
2. Yanger K, Knigin D, Zong Y, Maggs L, Gu G, Akiyama H, Pikarsky E, Stanger BZ: Adult hepatocytes are generated by self-duplication rather than stem cell differentiation. *Cell Stem Cell* 2014, 15:340–349
3. Dooley S, ten Dijke P: TGF-beta in progression of liver disease. *Cell Tissue Res* 2012, 347:245–256
4. Han C, Bowen WC, Li G, Demetris AJ, Michalopoulos GK, Wu T: Cytosolic phospholipase A2alpha and peroxisome proliferator-activated receptor gamma signaling pathway counteracts transforming growth factor beta-mediated inhibition of primary and transformed hepatocyte growth. *Hepatology* 2010, 52:644–655
5. McMahon JB, Richards WL, del Campo AA, Song MK, Thorgeirsson SS: Differential effects of transforming growth factor-beta on proliferation of normal and malignant rat liver epithelial cells in culture. *Cancer Res* 1986, 46:4665–4671
6. Russell WE, Coffey RJ, Ouellette AJ, Moses HL: Type beta transforming growth factor reversibly inhibits the early proliferative response to partial hepatectomy in the rat. *Proc Natl Acad Sci U S A* 1988, 85:5126–5130
7. Ichikawa T, Zhang YQ, Kogure K, Hasegawa Y, Takagi H, Mori M, Kojima I: Transforming growth factor beta and activin tonically inhibit DNA synthesis in the rat liver. *Hepatology* 2001, 34:918–925
8. Michalopoulos GK: Hepatostat: liver regeneration and normal liver tissue maintenance. *Hepatology* 2017, 65:1384–1392
9. Michalopoulos GK: Liver regeneration. *J Cell Physiol* 2007, 213: 286–300
10. Kulkarni AB, Huh CG, Becker D, Geiser A, Lyght M, Flanders KC, Roberts AB, Sporn MB, Ward JM, Karlsson S: Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. *Proc Natl Acad Sci U S A* 1993, 90: 770–774
11. Im YH, Kim HT, Kim IY, Factor VM, Hahm KB, Anzano M, Jang JJ, Flanders K, Haines DC, Thorgeirsson SS, Sizeland A, Kim SJ: Heterozygous mice for the transforming growth factor-beta type II

- receptor gene have increased susceptibility to hepatocellular carcinogenesis. *Cancer Res* 2001, 61:6665–6668
12. Kanzler S, Meyer E, Lohse AW, Schirmacher P, Henninger J, Galle PR, Blessing M: Hepatocellular expression of a dominant-negative mutant TGF-beta type II receptor accelerates chemically induced hepatocarcinogenesis. *Oncogene* 2001, 20:5015–5024
  13. Worthington JJ, Klementowicz JE, Travis MA: TGFbeta: a sleeping giant awoken by integrins. *Trends Biochem Sci* 2011, 36:47–54
  14. Hynes RO: Integrins: bidirectional, allosteric signaling machines. *Cell* 2002, 110:673–687
  15. Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalton SL, Wu J, Pittet JF, Kaminski N, Garat C, Matthey MA, Rifkin DB, Sheppard D: The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. *Cell* 1999, 96:319–328
  16. Mu D, Cambier S, Fjellbirkeland L, Baron JL, Munger JS, Kawakatsu H, Sheppard D, Broaddus VC, Nishimura SL: The integrin alpha(v)beta8 mediates epithelial homeostasis through MT1-MMP-dependent activation of TGF-beta1. *J Cell Biol* 2002, 157:493–507
  17. Asano Y, Ihn H, Yamane K, Jinnin M, Mimura Y, Tamaki K: Increased expression of integrin alpha(v)beta3 contributes to the establishment of autocrine TGF-beta signaling in scleroderma fibroblasts. *J Immunol* 2005, 175:7708–7718
  18. Asano Y, Ihn H, Yamane K, Jinnin M, Mimura Y, Tamaki K: Involvement of alphavbeta5 integrin-mediated activation of latent transforming growth factor beta1 in autocrine transforming growth factor beta signaling in systemic sclerosis fibroblasts. *Arthritis Rheum* 2005, 52:2897–2905
  19. Reed NI, Jo H, Chen C, Tsujino K, Arnold TD, DeGrado WF, Sheppard D: The alphavbeta1 integrin plays a critical in vivo role in tissue fibrosis. *Sci Transl Med* 2015, 7:288ra79
  20. Shi M, Zhu J, Wang R, Chen X, Mi L, Walz T, Springer TA: Latent TGF-beta structure and activation. *Nature* 2011, 474:343–349
  21. Henderson NC, Arnold TD, Katamura Y, Giacomini MM, Rodriguez JD, McCarty JH, Pellicoro A, Raschperger E, Betsholtz C, Ruminski PG, Griggs DW, Prinsen MJ, Maher JJ, Iredale JP, Lacy-Hulbert A, Adams RH, Sheppard D: Targeting of alphav integrin identifies a core molecular pathway that regulates fibrosis in several organs. *Nat Med* 2013, 19:1617–1624
  22. Aluwihare P, Mu Z, Zhao Z, Yu D, Weinreb PH, Horan GS, Violette SM, Munger JS: Mice that lack activity of alphavbeta6- and alphavbeta8-integrins reproduce the abnormalities of Tgfb1- and Tgfb3-null mice. *J Cell Sci* 2009, 122:227–232
  23. Popov Y, Patsenker E, Stickel F, Zaks J, Bhaskar KR, Niedobitek G, Kolb A, Friess H, Schuppan D: Integrin alphavbeta6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies. *J Hepatol* 2008, 48:453–464
  24. Peng ZW, Ikenaga N, Liu SB, Sverdlov DY, Vaid KA, Dixit R, Weinreb PH, Violette S, Sheppard D, Schuppan D, Popov Y: Integrin alphavbeta6 critically regulates hepatic progenitor cell function and promotes ductular reaction, fibrosis, and tumorigenesis. *Hepatology* 2016, 63:217–232
  25. Fenton TM, Kelly A, Shuttleworth EE, Smedley C, Atakilit A, Powrie F, Campbell S, Nishimura SL, Sheppard D, Levison S, Worthington JJ, Lehtinen MJ, Travis MA: Inflammatory cues enhance TGFbeta activation by distinct subsets of human intestinal dendritic cells via integrin alphavbeta8. *Mucosal Immunol* 2017, 10: 624–634
  26. Reboldi A, Armon TI, Rodda LB, Atakilit A, Sheppard D, Cyster JG: IgA production requires B cell interaction with subepithelial dendritic cells in Peyer's patches. *Science* 2016, 352:aaf4822
  27. Travis MA, Reizis B, Melton AC, Masteller E, Tang Q, Proctor JM, Wang Y, Bernstein X, Huang X, Reichardt LF, Bluestone JA, Sheppard D: Loss of integrin alpha(v)beta8 on dendritic cells causes autoimmunity and colitis in mice. *Nature* 2007, 449:361–365
  28. Worthington JJ, Kelly A, Smedley C, Bauché D, Campbell S, Marie JC, Travis MA: Integrin alphavbeta8-mediated TGF-beta activation by effector regulatory T cells is essential for suppression of T-cell-mediated inflammation. *Immunity* 2015, 42:903–915
  29. Arnold TD, Niaudet C, Pang M-F, Siegenthaler J, Gaengel K, Jung B, Ferrero GM, Mukoyama Y-S, Fuxe J, Akhurst R, Betsholtz C, Sheppard D, Reichardt LF: Excessive vascular sprouting underlies cerebral hemorrhage in mice lacking alphaVbeta8-TGFbeta signaling in the brain. *Development* 2014, 141:4489–4499
  30. Minagawa S, Lou J, Seed RI, Cormier A, Wu S, Cheng Y, Murray L, Tsui P, Connor J, Herbst R, Govaerts C, Barker T, Cambier S, Yanagisawa H, Goodsell A, Hashimoto M, Brand OJ, Cheng R, Ma R, McKnelly KJ, Wen W, Hill A, Jablons D, Wolters P, Kitamura H, Araya J, Barczak AJ, Erle DJ, Reichardt LF, Marks JD, Baron JL, Nishimura SL: Selective targeting of TGF-beta activation to treat fibroinflammatory airway disease. *Sci Transl Med* 2014, 6: 241ra79
  31. Fjellbirkeland L, Cambier S, Broaddus VC, Hill A, Brunetta P, Dolganov G, Jablons D, Nishimura SL: Integrin alphavbeta8-mediated activation of transforming growth factor-beta inhibits human airway epithelial proliferation in intact bronchial tissue. *Am J Pathol* 2003, 163:533–542
  32. Postic C, Shiota M, Niswender KD, Jetton TL, Chen Y, Moates JM, Shelton KD, Lindner J, Cherrington AD, Magnuson MA: Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase. *J Biol Chem* 1999, 274:305–315
  33. Proctor JM, Zang K, Wang D, Wang R, Reichardt LF: Vascular development of the brain requires beta8 integrin expression in the neuroepithelium. *J Neurosci* 2005, 25:9940–9948
  34. Foo SS, Turner CJ, Adams S, Compagni A, Aubyn D, Kogata N, Lindblom P, Shani M, Zicha D, Adams RH: Ephrin-B2 controls cell motility and adhesion during blood-vessel-wall assembly. *Cell* 2006, 124:161–173
  35. Mitchell C, Willenbring H: A reproducible and well-tolerated method for 2/3 partial hepatectomy in mice. *Nat Protoc* 2008, 3:1167–1170
  36. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, Tinevez J-Y, White DJ, Hartenstein V, Eliceiri K, Tomancak P, Cardona A: Fiji: an open-source platform for biological-image analysis. *Nat Methods* 2012, 9:676–682
  37. Willems E, Leyns L, Vandesompele J: Standardization of real-time PCR gene expression data from independent biological replicates. *Anal Biochem* 2008, 379:127–129
  38. Smyth GK: Linear models and empirical bayes methods for assessing differential expression in microarray experiments. *Stat Appl Genet Mol Biol* 2004, 3:Article 3
  39. Ritchie ME, Silver J, Oshlack A, Holmes M, Diyagama D, Holloway A, Smyth GK: A comparison of background correction methods for two-colour microarrays. *Bioinformatics* 2007, 23: 2700–2707
  40. Bolstad BM, Irizarry RA, Åstrand M, Speed TP: A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. *Bioinformatics* 2003, 19:185–193
  41. Holm S: A simple sequentially rejective multiple test procedure. *Scand J Stat* 1979, 6:65–70
  42. Alexa A, Rahnenführer J, Lengauer T: Improved scoring of functional groups from gene expression data by decorrelating GO graph structure. *Bioinformatics* 2006, 22:1600–1607
  43. Ebrahimkhani MR, Oakley F, Murphy LB, Mann J, Moles A, Perugorria MJ, Ellis E, Lakey AF, Burt AD, Douglass A, Wright MC, White SA, Jaffré F, Maroteaux L, Mann DA: Stimulating healthy tissue regeneration by targeting the 5-HT<sub>2B</sub> receptor in chronic liver disease. *Nat Med* 2011, 17:1668–1673
  44. Mogler C, Wieland M, König C, Hu J, Runge A, Korn C, Besemfelder E, Breitkopf-Heinlein K, Komljenovic D, Dooley S, Schirmacher P, Longerich T, Augustin HG: Hepatic stellate cell-expressed endosialin balances fibrogenesis and hepatocyte proliferation during liver damage. *EMBO Mol Med* 2015, 7:332–338

45. DeLeve LD: Liver sinusoidal endothelial cells and liver regeneration. *J Clin Invest* 2013, 123:1861–1866
46. Ding B-S, Nolan DJ, Butler JM, James D, Babazadeh AO, Rosenwaks Z, Mittal V, Kobayashi H, Shido K, Lyden D, Sato TN, Rabbany SY, Rafii S: Inductive angiocrine signals from sinusoidal endothelium are required for liver regeneration. *Nature* 2010, 468:310–315
47. Ding B-S, Cao Z, Lis R, Nolan DJ, Guo P, Simons M, Penfold ME, Shido K, Rabbany SY, Rafii S: Divergent angiocrine signals from vascular niche balance liver regeneration and fibrosis. *Nature* 2014, 505:97–102
48. Nishimura SL, Sheppard D, Pytela R: Integrin  $\alpha v \beta 8$ . Interaction with vitronectin and functional divergence of the  $\beta 8$  cytoplasmic domain. *J Biol Chem* 1994, 269:28708–28715
49. Venstrom K, Reichardt L:  $\beta 8$  integrins mediate interactions of chick sensory neurons with laminin-1, collagen IV, and fibronectin. *Mol Biol Cell* 1995, 6:419–431
50. Coulouarn C, Factor VM, Thorgeirsson SS: Transforming growth factor- $\beta$  gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. *Hepatology* 2008, 47:2059–2067
51. Mars WM, Zarnegar R, Michalopoulos GK: Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA. *Am J Pathol* 1993, 143:949–958
52. Bezerra JA, Currier AR, Melin-Aldana H, Sabla G, Bugge TH, Kombrinck KW, Degen JL: Plasminogen activators direct reorganization of the liver lobule after acute injury. *Am J Pathol* 2001, 158:921–929
53. Wang H, Zhang Y, Heuckeroth RO: Tissue-type plasminogen activator deficiency exacerbates cholestatic liver injury in mice. *Hepatology* 2007, 45:1527–1537
54. Huang J, Schrieffer AE, Clifton PF, Dietzen D, Kulkarni S, Sing S, Monga SP, Rudnick DA: Postponing the hypoglycemic response to partial hepatectomy delays mouse liver regeneration. *Am J Pathol* 2016, 186:587–599
55. Matsuo T, Yamaguchi S, Mitsui S, Emi A, Shimoda F, Okamura H: Control mechanism of the circadian clock for timing of cell division in vivo. *Science* 2003, 302:255–259